These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16720232)

  • 1. Treatment approaches and nursing considerations for non-Hodgkin's lymphoma.
    Long J; Versea L
    Semin Oncol Nurs; 2006 May; 22(2):97-106. PubMed ID: 16720232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a new monoclonal antibody therapy for non-Hodgkin's lymphoma.
    Kosits C; Callaghan M
    Oncol Nurs Forum; 2000; 27(1):51-9. PubMed ID: 10660923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment approaches and nursing applications for non-Hodgkin lymphoma.
    Long JM
    Clin J Oncol Nurs; 2007 Feb; 11(1 Suppl):13-21. PubMed ID: 17471823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
    Maloney DG
    J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for HIV-associated non-Hodgkin's lymphoma.
    Newsom-Davis T; Ahamed E; Bower M
    Expert Opin Biol Ther; 2009 Oct; 9(10):1313-24. PubMed ID: 19645631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of non-Hodgkin's lymphoma: biology, staging, and treatment.
    Fisher RI
    Semin Oncol; 2003 Apr; 30(2 Suppl 4):3-9. PubMed ID: 12728402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic cell transplantation in non-Hodgkin's lymphoma.
    Steingass SK
    Semin Oncol Nurs; 2006 May; 22(2):107-16. PubMed ID: 16720233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients.
    Coiffier B
    Haematologica; 1999 Jun; 84 Suppl EHA-4():14-8. PubMed ID: 10907457
    [No Abstract]   [Full Text] [Related]  

  • 9. Radioimmunotherapy for non-Hodgkin's lymphoma.
    Liebenguth P; Vogt Temple S
    Semin Oncol Nurs; 2006 Nov; 22(4):257-66. PubMed ID: 17095402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.
    LaCasce AS; Freedman AS
    Semin Hematol; 2008 Apr; 45(2):85-9. PubMed ID: 18381102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of non-Hodgkin's lymphoma.
    Rogers BB
    Semin Oncol Nurs; 2006 May; 22(2):67-72. PubMed ID: 16720228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma.
    Motta G; Cea M; Carbone F; Augusti V; Moran E; Patrone F; Nencioni A
    J BUON; 2011; 16(1):9-15. PubMed ID: 21674844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
    Zinzani PL; Martelli M; Poletti V; Vitolo U; Gobbi PG; Chisesi T; Barosi G; Ferreri AJ; Marchetti M; Pimpinelli N; Tura S; ; ;
    Haematologica; 2008 Sep; 93(9):1364-71. PubMed ID: 18603558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the management of patients with non-Hodgkin's lymphoma.
    Lionberger JM; Armitage JO
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):43-52. PubMed ID: 12113132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphoma.
    Friedberg JW
    Haematologica; 2006 Nov; 91(11):1453-5. PubMed ID: 17082005
    [No Abstract]   [Full Text] [Related]  

  • 18. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.
    Akhtar S; Maghfoor I
    J Clin Oncol; 2005 Sep; 23(25):6261; author reply 6262. PubMed ID: 16135496
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa.
    Shome D; Esmaeli B
    Curr Opin Ophthalmol; 2008 Sep; 19(5):414-21. PubMed ID: 18772675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.